GSK plc

Open: 36.95 Close: 37.1 Change: 0.15

The best way to get informed about GSK plc Company Inc Stock without reading hundreds of pages.

How much time have you spent trying to decide whether investing in GSK plc? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about GSK plc are: …

Concept Map

Semantic Network

Stock Summary

GSK plc engages in the research, development and manufacture of vaccines and specialty medicines. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company was formerly known as Gl.

Today's Summary

GSK is up 21.40% so far this year after the company closed yesterday at $36.65 per share. Shingrix is currently GSKs biggest product and strongest growth driver, taking in 1.7 billion pounds in first-half sales.

Today's News

GSK is up 21.40% so far this year after the company closed yesterday at $36.65. The overall score measures the companys performance based-off both short and long term indicators and means that GSK scores better than 80% of the overall market. GSK will sell £2.5 billion ($3 billion) worth of its Shingrix shot to Chinas Zhifei over a three-year period. Under the agreement, GSK to promote the shot across 30,000 vaccination points. GSK shares were up 1.2% by 0812 GMT, near their session high. Shingrix is currently GSKs biggest product and strongest growth driver, taking in 1.7 billion pounds in first-half sales. In the year 2022, GSK had annual revenue of $35.33B with 7.30% growth. GSK plc (LSE/NYSE: GSK) announced that it intends to sell 270m ordinary shares in Haleon, equivalent to approximately 2.9% of Haleons issued share capital. GSK cautions investors that any forward-looking statements or projections made by GSK are subject to risks and uncertainties. GSK will sell £2.5 billion ($3 billion) of its Shingrix shot to Chinese vaccine maker Chongqing Zhifei Biological Products Co. The partnership aims to boost GSKs commitment to double Shingles sales globally to more than £4bn. GSK stock price per share is $36.65 per share (NYSE: GSK) Gsk trades on the NYSE under the ticker symbol GSK. GSK currently has 4,048,913,043 outstanding shares. GSK plc has an exclusive agreement with Chongqing Zhifei Biological Products to co-promote its shingles vaccine Shingrix in China. GSK announced positive data from the ZOSTER-076 phase IV trial showing that Shingrix demonstrated 100% vaccine efficacy. GlaxoSmithKline PLC joined forces with the China-based Zhifei to expand its global market share for its vaccine shingles. Partnership will significantly extend availability of Shingrix in China with co-promotion to healthcare professionals. GSK sells $1.1 billion stake in former consumer unit haleon. Japans Ministry of Health, Labour and Welfare approves GSKs Arexvy, the countrys first respiratory syncytial virus vaccine. GSK intends to sell 270 mln ordinary shares in haleon. GSK will hold 685m 1  ordinary shares in Haleon, representing approximately 7.4% of the issued share capital. Emma Walmsley will succeed Sir Andrew Witty as CEO of GSK after he retires on 31 March 2017. Follow us over the next hour as we go #BehindTheScience and #ThroughTheLabs. Follow us on Twitter @GSK and @GSK for six weeks. GSK joins the world in mourning the death of Her Majesty, Queen Elizabeth II. GSK is committed to tackling #COVID19 together.

Stock Profile

"GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom."

Keywords

Are looking for the most relevant information about GSK plc? Investor spend a lot of time searching for information to make investment decisions in GSK plc. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about GSK plc are: GSK, share, sell, Shingrix, vaccine, Zhifei, shot, and the most common words in the summary are: gsk, stock, market, news, plc, vaccine, share, . One of the sentences in the summary was: Shingrix is currently GSKs biggest product and strongest growth driver, taking in 1.7 billion pounds in first-half sales.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gsk #stock #market #news #plc #vaccine #share.